Ascletis Pharma (ASCLF) Stock Price, News & Analysis

Company Overview

Ascletis Pharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company has historically concentrated on areas of significant unmet medical need, including viral diseases, oncology and metabolic disorders, with operations and commercial activities centered primarily in China.

Ascletis’ portfolio has included therapies for infectious diseases and viral hepatitis. Its best-known product is Ganovo (danoprevir), a hepatitis C treatment developed for use in combination with other antiviral medicines and approved in China. The company has also advanced a pipeline of drug candidates in areas such as oncology, HIV, hepatitis B and metabolic disease, although the status of individual programs may change as clinical development progresses.

Ascletis was founded in 2013 by Jason Yang, who has served as the company’s chairman and chief executive officer. The company completed an initial public offering on the Hong Kong Stock Exchange in 2018 and has continued to pursue in-house research, licensing and commercialization partnerships to expand its product portfolio. Its primary geographic focus has been the Chinese market, supported by research and development activities aimed at broader opportunities.

Key Stats

• Today's Range: $1.04 to $1.04
• 50-Day Range: $1.04 to $1.34
• 52-Week Range: $1.04 to $2.50
• Volume: 5,000 shs
• Average Volume: 2,681 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ASCLF
• CIK: N/A
• Web: www.ascletis.com
• Phone: 86-571-8538-9730
• Fax: N/A
• Employees: 219
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A